Evidence map›Paper›PMID 30497977›Full record

ArticleEBioMedicine2018

Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery.

Baharak Bahmani, Mayuko Uehara, Farideh Ordikhani, Xiaofei Li, Liwei Jiang, Naima Banouni, Takaharu Ichimura, Vivek Kasinath, Siawosh K Eskandari, Nasim Annabi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Histochemistry for Molecular Imaging in Nanomedicine.International journal of molecular sciences · 2024
    Review
  7. Review
  8. Article
  9. Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes.Advanced materials (Deerfield Beach, Fla.) · 2023
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Baharak BahmaniTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Mayuko UeharaTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Farideh OrdikhaniTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Xiaofei LiTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Liwei JiangTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Naima BanouniTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Takaharu IchimuraRenal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Vivek KasinathTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Siawosh K EskandariTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Nasim AnnabiDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, CA 90095, USA.
Jonathan S BrombergDepartment of Surgery and Microbiology and Immunobiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Leonard D ShultzDepartment of Immunology, The Jackson Laboratory, Bar Harbor, ME 04609, USA.
Dale L GreinerDepartment of Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Reza AbdiTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: rabdi@rics.bwh.harvard.edu.

Funding

Lymph Node Structure and Function in Tolerance: Role of LamininsR01AI114496 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BROMBERG, JONATHAN S · 2015 to 2024
$4.2M
Organ Design and Engineering Training Program (ODET Program)T32EB016652 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2014 to 2023
$3.5M
Protection of organ transplant from ischemia reperfusion injuriesR01AI126596 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ABDI, REZA · 2016 to 2020
$2.6M
Lymph Node Delivery in TransplantationU01AI170056 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ABDI, REZA · 2022 to 2025
$2.3M
PI3K-gamma regulates T cell mediated alloimmunityR01HL141815 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ABDI, REZA · 2018 to 2021
$1.6M
NHLBI NIH HHS R01 HL141815NIAID NIH HHS R01 AI114496NIAID NIH HHS R01 AI126596NIAID NIH HHS U01 AI170056NIBIB NIH HHS T32 EB016652
6 · The paper itself

Abstract

backgroundNanomedicine offers an excellent opportunity to tackle treatment-refractory malignancies by enhancing the delivery of therapeutics to the tumor site. High endothelial venules (HEVs) are found primarily in lymph nodes or formed de novo in peripheral tissues during inflammatory responses. They express peripheral node addressin (PNAd), which is recognized by the monoclonal antibody MECA79.

methodsHere, we demonstrated that HEVs form de novo in human pancreatic ductal adenocarcinoma (PDAC). We engineered MECA79 coated nanoparticles (MECA79-NPs) that recognize these ectopic HEVs in PDAC.

findingsThe trafficking of MECA79-NPs following intravenous delivery to human PDAC implanted in a humanized mouse model was more robust than non-conjugated NPs. Treatment with MECA79-Taxol-NPs augmented the delivery of Paclitaxel (Taxol) to the tumor site and significantly reduced the tumor size. This effect was associated with a higher apoptosis rate of PDAC cells and reduced vascularization within the tumor.

interpretationTargeting the HEVs of PDAC using MECA79-NPs could lay the ground for the localized delivery of a wide variety of drugs including chemotherapeutic agents. FUND: National Institutes of Health (NIH) grants: T32-EB016652 (B·B.), NIH Cancer Core Grant CA034196 (L.D.S.), National Institute of Allergy and Infectious Diseases grants R01-AI126596 and R01-HL141815 (R.A.).

Indexed as

Neovascularization, PathologicAnimalsAntineoplastic AgentsBiomarkersCarcinoma, Pancreatic DuctalCell LineDisease Models, AnimalEndothelium, LymphaticFemaleHumansImmunohistochemistryLymph NodesMaleMiceMolecular Targeted TherapyNanoparticlesAntineoplastic AgentsBiomarkersPaclitaxelHigh endothelial venulesMECA79 coated nanoparticlesPancreatic ductal adenocarcinomaPeripheral node addressinTaxol

Identifiers

PMID30497977
PMCPMC6306381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.